Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction
Status:
Withdrawn
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
To assess the effect of ARNI on myocardial deoxygenation at stress and myocardial fibrosis,
and correlate this to changes in myocardial systolic and diastolic function in HFpEF
patients.
Phase:
Phase 3
Details
Lead Sponsor:
Flinders University
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan